June 22, 10 am EST
Webinar Highlights
You will learn:
- The importance of developing CAR-T enrichment strategies
- A strategy for engineered T cell enrichment using an anti-human αβTCR antibody
- Methods for characterizing antibodies
- How antibody de novo sequencing works
- How HDX epitope mapping works
Abstract
Since 2017 6 CAR-T therapies have been approved by the FDA. Over 500 clinical trials involving CAR-T are ongoing and the $2Bn market is expected to grow at over 35% year over year. It is an incredibly promising class of therapy for cancer treatment. Yet, many candidate therapies see disappointing response rates in clinical trials – perhaps resulting from poorly engineered (or non engineered) T cells persisting in the administered product and causing a conflict with the patient’s immune system. Many teams are therefore working on methods to better enrich and purify engineered T cells.
Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.
Speaker Bios
Monique Seymour, MSc
Rapid Novor
International Scientific Sales Executive
Monique Seymour graduated from the University of Glasgow with a Master’s in Biotechnology and Management. She enjoys working with scientists in both Diagnostic and Therapeutic areas to understand their research goals and ensure next generation protein sequencing enables and/or complements current or new workflows to mitigate risk and deliver reproducible projects. Monique is passionate about furthering life sciences research to improve global patient health.
Patricia Hernández López
UMC Utrecht
PhD Student
Patricia is a PhD candidate with Prof. Jürgen Kuball’s group at University Medical Centre Utrecht, and one of the authors of the above-mentioned paper. She holds a degree in Health Biology and a Master’s degree in Therapeutic Targets in Cell Signaling: Research and Development. She has experience in the biomedical research sector, mainly in molecular biology and cancer research, including Stem Cell research.
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics